Drugs and Devices
by Jenna Ogilvie | Jul 31, 2017 | Discussion Paper, Perspectives
The antibiotic resistance problem is caused by the evolution and transfer of genes that confer resistance to medically important antibiotics into human pathogens. The acquisition of such resistance genes by pathogens complicates disease treatment, increases...
by Jenna Ogilvie | Jun 23, 2017 | Discussion Paper, Perspectives
Recent advances in cell biology and genetic engineering have changed the way we think about medicine. Indeed, we are witnessing a potential shift from the traditional paradigm of health care to one with greater focus on the possibility of regenerative and...
by Jenna Ogilvie | Mar 17, 2017 | Discussion Paper, Perspectives
Health care professionals, including emergency response personnel, face unique occupational health and safety challenges, one of which is exposure to uncontrolled airborne infectious particles. To protect themselves, these professionals rely heavily on N95...
by Laura DeStefano | Sep 19, 2016 | Discussion Paper, Perspectives
About the Vital Directions for Health and Health Care Series This publication is part of the National Academy of Medicine’s Vital Directions for Health and Health Care Initiative, which called on more than 100 leading researchers, scientists, and policy makers from...
by Laura DeStefano | Sep 19, 2016 | Discussion Paper, Perspectives
About the Vital Directions for Health and Health Care Series This publication is part of the National Academy of Medicine’s Vital Directions for Health and Health Care Initiative, which called on more than 100 leading researchers, scientists, and policy makers from...
by Jenna Ogilvie | Jul 20, 2016 | Discussion Paper, Perspectives
Problem Statement Declining or stagnant research and development (R&D) productivity has led many observers to argue that the current paradigm for drug discovery and development requires disruptive innovation (The term “disruptive innovation” is...
by Jenna Ogilvie | Jul 1, 2016 | Commentary, Perspectives
Now in its third year of data disclosure, the Physician Payments Sunshine Act has helped demystify financial connections between two critically linked health sector stakeholders: health care providers and pharmaceutical companies. This week, the 2015 figures...
by Jenna Ogilvie | May 5, 2016 | Discussion Paper, Perspectives
Individuals make decisions about health and well-being every day. Many of those decisions involve using and understanding numbers, and most of the decisions are made quickly, at home or at work, as a person goes about a daily routine. Even with adequate time,...
by Laura DeStefano | Sep 11, 2015 | Discussion Paper, Perspectives
Abstract Despite the fact that they have gone through a rigorous approval process, uncertainty about newly approved drugs always exists. The uncertainty is amplified when drugs are approved on preliminary or interim evidence (i.e., accelerated approval) or on...
by Laura DeStefano | Jun 23, 2015 | Discussion Paper, Perspectives
ABSTRACT Background: Despite greater spending on health care and biomedical research, the United States has poorer health outcomes than competitive nations. Information is needed on the potential impact of interventions to better guide resources allocation. Objective:...
